Your browser doesn't support javascript.
loading
The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
Jarius, S; Eichhorn, P; Franciotta, D; Petereit, H F; Akman-Demir, G; Wick, M; Wildemann, B.
Afiliação
  • Jarius S; Molecular Neuroimmunology Group, Department of Neurology, Otto Meyerhof Center, University of Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.
  • Eichhorn P; Institute of Laboratory Medicine, Klinikum Großhadern, Ludwig Maximilian University, Munich, Germany.
  • Franciotta D; IRCCS, National Neurological Institute C. Mondino, Pavia, Italy.
  • Petereit HF; Praxis rechts vom Rhein, Cologne, Germany.
  • Akman-Demir G; Department of Neurology, Istanbul Bilim University, Istanbul, Turkey.
  • Wick M; Institute of Laboratory Medicine, Klinikum Großhadern, Ludwig Maximilian University, Munich, Germany.
  • Wildemann B; Molecular Neuroimmunology Group, Department of Neurology, Otto Meyerhof Center, University of Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany.
J Neurol ; 264(3): 453-466, 2017 Mar.
Article em En | MEDLINE | ID: mdl-28005176
BACKGROUND: It has long been known that the majority of patients with multiple sclerosis (MS) display an intrathecal, polyspecific humoral immune response to a broad panel of neurotropic viruses. This response has measles virus, rubella virus and varicella zoster virus as its most frequent constituents and is thus referred to as the MRZ reaction (MRZR). OBJECTIVE: Re-evaluation of the specificity of MRZR as a marker of MS. METHODS: Structured review of the existing English-, German- and Spanish-language literature on MRZR testing, with evaluation of MRZR in a cohort of 43 unselected patients with MS and other neurological diseases as a proof of principle. RESULTS: A positive MRZ reaction, defined as a positive intrathecal response to at least two of the three viral agents, was found in 78% of MS patients but only in 3% of the controls (p < 0.00001), corresponding to specificity of 97%. Median antibody index values were significantly lower in non-MS patients (measles, p < 0.0001; rubella, p < 0.006; varicella zoster, p < 0.02). The 30 identified original studies on MRZR reported results from 1478 individual MRZR tests. A positive MRZR was reported for 458/724 (63.3%) tests in patients with MS but only for 19/754 (2.5%) tests in control patients (p < 0.000001), corresponding to cumulative specificity of 97.5% (CI 95% 96-98.4), cumulative sensitivity of 63.3% (CI 95% 59.6-66.8) (or 67.4% [CI 95% 63.5-71.1] in the adult MS subgroup), a positive likelihood ratio of 25.1 (CI 95% 16-39.3) and a negative likelihood ratio of 0.38 (CI 95% 0.34-0.41). Of particular note, MRZR was absent in 52/53 (98.1%) patients with neuromyelitis optica or MOG-IgG-positive encephalomyelitis, two important differential diagnoses of MS. CONCLUSION: MRZR is the most specific laboratory marker of MS reported to date. If present, MRZR substantially increases the likelihood of the diagnosis of MS. Prospective and systematic studies on the diagnostic and prognostic impact of MRZR testing are highly warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Rubéola / Herpesvirus Humano 3 / Vírus do Sarampo / Anticorpos Antivirais / Esclerose Múltipla Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Rubéola / Herpesvirus Humano 3 / Vírus do Sarampo / Anticorpos Antivirais / Esclerose Múltipla Idioma: En Ano de publicação: 2017 Tipo de documento: Article